室性心律失常的治疗研究进展

摘要/Abstract

摘要： 随着医学技术的不断发展,室性心律失常的治疗取得了显著进展。药物治疗方面,胺碘酮等抗心律失常药物仍是主要手段,导管消融技术不断进步,三维电解剖标测系统和影像学技术的应用提高了消融的成功率和安全性。ICD技术也取得了显著进展,全皮下ICD减少了并发症,且程控功能不断优化。基因治疗作为新兴手段,显示出巨大潜力。未来,室性心律失常的治疗将更加注重个体化和精准化,基因检测技术的发展将为个体化治疗提供可能,新的药物研发和治疗技术的不断涌现也将为治疗带来更多选择和希望。

陈嘉莹. 室性心律失常的治疗研究进展[J]. 心血管病防治知识, 2025, 15(19): 142-144.

参考文献

[1] Zeppenfeld K, Tfelt-Hansen J, de Riva M, et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death[J]. Eur Heart J, 2022, 43(40):3997-4126.
[2] Chatzidou S, Kontogiannis C, Tsilimigras DI, et al.Propranolol Versus Metoprolol for Treatment of Electrical Storm in Patients With Implantable Cardioverter-Defibrillator[J]. J Am Coll Cardiol, 2018, 71(17):1897-1906.
[3] Yin Y, Abubakar SM, Tan S, et al.A 2.63 μW ECG Processor With Adaptive Arrhythmia Detection and Data Compression for Implantable Cardiac Monitoring Device[J]. IEEE Trans Biomed Circuits Syst, 2021, 15(4):777-790.
[4] Gomez SE, Larson J, Hlatky MA, et al.Prevalence of frequent premature ventricular contractions and nonsustained ventricular tachycardia in older women screened for atrial fibrillation in the Women's Health Initiative[J]. Heart rhythm, 2024, 21(8):1280-1288.
[5] Leyva F, Zegard A, Okafor O, et al.Myocardial Fibrosis Predicts Ventricular Arrhythmias and Sudden Death After Cardiac Electronic Device Implantation[J]. J Am Coll Cardiol, 2022, 79(7):665-678.
[6] Arbelo E, Protonotarios A, Gimeno JR, et al.2023 ESC Guidelines for the management of cardiomyopathies[J]. Eur Heart J, 2023, 44(37):3503-3626.
[7] Torrado J, Sima A, Comstuck C, et al.Prevalence of frequent premature ventricular contractions and left-ventricular systolic dysfunction in patients receiving Holter monitoring[J]. J Cardiovasc Electrophysiol, 2025, 36(1):54-61.
[8] He X, Zhao M, Bi X, Sun L, Yu X, Zang W.Novel strategies and underlying protective mechanisms of modulation of vagal activity in cardiovascular diseases[J]. Br J Pharmacol, 2015, 172(23):5489-5500.
[9] 任宇捷, 梁景辉, 侯婷婷, 王世强. β肾上腺素受体对心肌细胞钙信号的调控[J]. 中国科学:生命科学, 2024, 54(8):1346-1359.
[10] 韦怡春, 江华, 李菊香. 肾去交感神经术治疗室性心律失常的研究进展[J]. 临床心血管病杂志, 2016, 32(6):540-543.
[11] Mahajan A, Takamiya T, Benharash P, Zhou W.Effect of thoracic epidural anesthesia on heart rate variability in a porcine model[J]. Physiol Rep, 2017: 5(7).
[12] Rao BH, Lokre A, Patnala N, Padmanabhan TNC.Stellate ganglion ablation by conventional radiofrequency in patients with electrical storm[J] , Europace, 2023; 25(10).
[13] Miki Y, Yoshimura S, Sasaki T, et al.Bilateral Cardiac Sympathetic Denervation for Treatment-Resistant Ventricular Arrhythmias in Heart Failure Patients with a Reduced Ejection Fraction[J]. Int Heart J, 2022, 63(4):692-699.
[14] Qiu X, Feng Z, Lin C.Effect of Renal Sympathetic Denervation on Ventricular Electrical Activity in Myocardial Infarction[J]. Tohoku J Exp Med, 2024, 264(1):41-48.
[15] Batul SA, Olshansky B, Fisher JD, Gopinathannair R.Recent advances in the management of ventricular tachyarrhythmias[J]. F1000Res, 2017, 6:1027.
[16] Bhatia NK, Halaby RN, Bruce CG, et al. Ventricular Intramyocardial Navigation for Tachycardia Ablation Guided by Electrograms (VINTAGE): Initial Human Experience[J]. JACC Clin Electrophysiol,2025, null.
[17] de Campos M, Moraes VRY, Daher RF, et al. Pulsed-field ablation versus thermal ablation for atrial fibrillation: A meta-analysis[J]. Heart Rhythm O2, 2024, 5(6):385-395.
[18] Padisak A, Szegedi N, Tanai E, et al.Pulsed field ablation for ventricular arrhythmias with pentaspline catheter[J]. Front Cardiovasc Med, 2025; 12:1631253.
[19] Wang X, Dennis A, Hesselkilde EM, et al.Machine learning approach for automated localization of ventricular tachycardia ablation targets from substrate maps: development and validation in a porcine model[J]. Eur Heart J Digit Health, 2025, 6(4):645-655.
[20] Sapp JL, Tang ASL, Parkash R, et al.A randomized clinical trial of catheter ablation and antiarrhythmic drug therapy for suppression of ventricular tachycardia in ischemic cardiomyopathy: The VANISH2 trial[J]. Am Heart J, 2024, 274:1-10.
[21] 陈嘉莹, 何利伟, 庄英渠. β₁-肾上腺素能受体基因多态性对STEMI患者室性心律失常和短期预后的影响[J]. 中国病理生理杂志, 2024, 40(09):1645-1651.
[22] Villiger L, Joung J, Koblan L, et al.CRISPR technologies for genome, epigenome and transcriptome editing[J]. Nat Rev Mol Cell Biol, 2024, 25(6):464-487.
[23] Bains S, Giammarino L, Nimani S, et al.KCNQ1 suppression-replacement gene therapy in transgenic rabbits with type 1 long QT syndrome[J]. Eur Heart J, 2024, 45(36):3751-3763.
[24] Sasaki N, Kok CY, Westhaus A, et al.In Search of Adeno-Associated Virus Vectors With Enhanced Cardiac Tropism for Gene Therapy[J]. Heart Lung Circ, 2023, 32(7):816-824.
[25] Martino RA, Wang Q, Xu H, et al.Vector Affinity and Receptor Distribution Define Tissue-Specific Targeting in an Engineered AAV Capsid[J]. J Virol, 2023, 97(6):e0017423.
[26] Yu J, Zhao X, Hao Y, et al.Inhibition of GRK4 reduces arrhythmia susceptibility and alleviates connexin43 dysregulation after myocardial infarction[J]. Biochem Pharmacol, 2025, 239:117035.
[27] Lodola F, Morone D, Denegri M, et al.Adeno-associated virus-mediated CASQ2 delivery rescues phenotypic alterations in a patient-specific model of recessive catecholaminergic polymorphic ventricular tachycardia[J]. Cell Death Dis, 2016, 7(10):e2393.
[28] Sapp JL, Tang ASL, Parkash R, et al.Catheter Ablation or Antiarrhythmic Drugs for Ventricular Tachycardia[J]. N Engl J Med, 2025, 392(8):737-747.
[29] Sapp JL, Wells GA, Parkash R, et al.Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs[J]. N Engl J Med, 2016, 375(2):111-121.
[30] Reichlin T, Kueffer T, Badertscher P, et al.Pulsed Field or Cryoballoon Ablation for Paroxysmal Atrial Fibrillation[J]. N Engl J Med, 2025, 392(15):1497-507.